The relevance of this gene to CML has recently been supported by several studies performed in patients, and strategies aimed at restoring its expression are expected to benefit the course of the disease by improving drug efficacy or contrasting the emergence of BCR/ABL1 mutants [15,16,17]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.